Followers | 4056 |
Posts | 151903 |
Boards Moderated | 3 |
Alias Born | 08/05/2009 |
![](https://investorshub.advfn.com/uicon/162645.png?cb=1681428050)
Wednesday, October 18, 2023 10:17:18 AM
but I am going to the gym so if it goes higher oh well
Recent ICU News
- Nuwellis Announces First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s QUELIMMUNE™ Therapy at Cincinnati Children’s • GlobeNewswire Inc. • 07/26/2024 01:00:00 PM
- First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s FDA-Approved QUELIMMUNE Therapeutic Device • GlobeNewswire Inc. • 07/23/2024 12:30:00 PM
- Nuwellis Marks First Commercial Sale of QUELIMMUNE™ Therapy to Cincinnati Children’s • GlobeNewswire Inc. • 07/17/2024 01:00:00 PM
- CMS Grants Category B Coverage for Adults with Acute Kidney Injury Enrolled in SeaStar Medical’s Selective Cytopheretic Device Pivotal Trial • GlobeNewswire Inc. • 07/16/2024 12:30:00 PM
- Edelson Lechtzin LLP Urges SeaStar Medical Holding Corporation (NASDAQ: ICU, ICUCW) Shareholders to Consult Legal Counsel About the Pending Securities Fraud Class Action • PR Newswire (US) • 07/12/2024 09:05:00 PM
- SeaStar Medical Ships First QUELIMMUNE Product Order to U.S. Distribution Partner • GlobeNewswire Inc. • 07/12/2024 12:30:00 PM
- SeaStar Medical Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 07/11/2024 08:05:00 PM
- SeaStar Medical Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 07/10/2024 01:00:00 PM
- SeaStar Medical Finalizes FDA Labeling Requirement for QUELIMMUNE, Paving the Way for First Commercial Sales as Humanitarian Use Device • GlobeNewswire Inc. • 07/03/2024 12:30:00 PM
- SeaStar Medical’s Selective Cytopheretic Device Featured in Two Presentations at the 42nd Vicenza Course AKI-CRT-ECOS and Critical Care Nephrology • GlobeNewswire Inc. • 06/11/2024 12:30:00 PM
- SeaStar Medical Strengthens Board of Directors and Transitions to Commercial-Stage Company • GlobeNewswire Inc. • 06/10/2024 12:30:00 PM
- Article in Nature Scientific Reports Describes Mechanism of Action of SeaStar Medical’s Selective Cytopheretic Device in the Immunomodulation of Excessive Inflammation • GlobeNewswire Inc. • 06/07/2024 12:30:00 PM
- SeaStar Medical Announces 25-for-1 Reverse Stock Split • GlobeNewswire Inc. • 06/06/2024 12:30:00 PM
- Manuscript Published on Multiorgan Failure Patients Treated with SeaStar Medical’s Selective Cytopheretic Device Who Achieved Transplant Eligibility • GlobeNewswire Inc. • 05/22/2024 12:30:00 PM
- SeaStar Medical Reports First Quarter 2024 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 05/14/2024 08:05:00 PM
- SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure • GlobeNewswire Inc. • 04/30/2024 12:30:00 PM
- SeaStar Medical Reports 2023 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 04/17/2024 08:00:00 PM
- SeaStar Medical to Present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 12:30:00 PM
- SeaStar Medical to Restate Financials, Sets Business Update Call for April 17 • GlobeNewswire Inc. • 03/27/2024 12:30:00 PM
- SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients • GlobeNewswire Inc. • 03/12/2024 12:30:00 PM
- SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024 • GlobeNewswire Inc. • 03/11/2024 08:05:00 PM
- Manuscript Discussing the Benefit of SeaStar Medical’s Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart Failure • GlobeNewswire Inc. • 02/27/2024 01:30:00 PM
- Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™ • GlobeNewswire Inc. • 02/22/2024 12:58:00 PM
- FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical’s Selective Cytopheretic Device for Pediatric Acute Kidney Injury • GlobeNewswire Inc. • 02/22/2024 12:53:00 PM
- SeaStar Medical Granted Canadian Patent with Broad Claims Covering the Selective Cytopheretic Device Technology • GlobeNewswire Inc. • 02/01/2024 01:30:00 PM
FEATURED POET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks • Aug 1, 2024 9:28 AM
Management Discusses Financial Filings of Global Arena Holding Inc., for 10-K 2023 and 10-Q, 1st Quarter 2024 • GAHC • Aug 1, 2024 9:14 AM
VAYK Announces LOI to Acquire $1 Million Home Service Company to Support Airbnb Business • VAYK • Aug 1, 2024 9:00 AM
Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM
Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM
Kona Gold Beverage Significantly Reduces Debt from Multiple Holders • KGKG • Jul 31, 2024 9:00 AM